Loading…
Swiss-listed specialty pharma focused on gastrointestinal drugs and endoscopy technology, using its MMX drug-delivery platform.
Swiss-listed specialty pharma focused on gastrointestinal drugs and endoscopy technology, using its MMX drug-delivery platform.
Moat: narrow (IP / patents). Patented MMX colon-targeted delivery technology licensed to pharma partners.
Headquarters: Zug, Switzerland · Employees: 324
Size Cosmo (CMHC.SW) is a Switzerland Health Care company (Pharmaceuticals: Major) with a market value of $1.17B, the 116th largest of 158 Switzerland companies the cockpit tracks. Shares closed at CHF 56.80 on 6 Nov 2026.
Performance Over six months the shares fell 24.8%, against -8.1% for the median peer and +11.6% for the Switzerland market (cap-weighted) — 4th lowest of 21 in its peer set.
Growth Revenue fell 44.7% over the last twelve months (peer median 0.0%); the operating margin is -13.3% (peer median 10.6%).
Valuation It trades at 432.6× forward earnings against a peer median of 19.6× (most expensive of 14).
Capital Return on invested capital runs 11.5 points below its cost of capital (8.6% WACC).
Next results Next results expected around 24 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CHF 95.0M | CHF 97.6M | CHF 254M | CHF 90.1M | CHF 102M |
| Revenue growth | — | -62% | +182% | -12% | — |
| Gross profit | CHF 43.3M | CHF 45.4M | CHF 209M | CHF 50.3M | CHF 57.8M |
| EBITDA | -CHF 559,550 | CHF 2.19M | CHF 150M | CHF 7.83M | CHF 40.2M |
| Net income | -CHF 5.85M | -CHF 3.38M | CHF 127M | -CHF 10.5M | CHF 17.3M |
| Free cash flow | -CHF 22.5M | -CHF 14.8M | CHF 151M | CHF 15.4M | CHF 26.6M |
| Capital expenditure | CHF 4.64M | CHF 5.12M | CHF 5.39M | CHF 4.27M | CHF 7.34M |
| Total debt | n/a | CHF 3.97M | CHF 2.07M | CHF 1.71M | CHF 178M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Cosmo CMHC.SW | $1.17B | -25% | -45% | -13% | 432.6× | n/a |
| Bausch Health Companies BHC.TO | $3.09B | +48% | +10% | 27% | 1.9× | -14.5% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | CMHC.SW | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +13.2% | -4.1% | 4th highest of 21 |
| 6-month return | -24.8% | -8.1% | 4th lowest of 21 |
| Distance from 52-week high | -56.1% | -27.5% | 3rd lowest of 21 |
| Revenue growth (TTM) | -44.7% | 0.0% | 2nd lowest of 19 |
| Operating margin | -13.3% | 10.6% | 5th lowest of 20 |
| Forward P/E | 432.6× | 19.6× | most expensive of 14 |
| ROIC minus cost of capital | -11.5 pp | -0.1 pp | 5th lowest of 19 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Cosmo CMHC.SW | Switzerland | $1.17B | -25% | -45% | -13% | 432.6× | n/a | n/a |
| Vetoquinol VETO.PA | France | $1.17B | +22% | -1% | 15% | 15.8× | -3.0% | +4.2% |
| Shanghai InnoStar Bio-tech 688710.SS | China | $1.17B | +28% | +24% | 6% | 85.2× | 16.2% | +19.4% |
| North China Pharmaceutical 600812.SS | China | $1.17B | -8% | -21% | 5% | n/a | 1.4% | -4.2% |
| Tianjin Ringpu Bio-technology 300119.SZ | China | $1.18B | -4% | -9% | 11% | 19.6× | 5.8% | +11.3% |
| GC Biopharma 006280.KS | South Korea | $1.18B | +2% | -3% | 4% | 5.0× | 8.3% | +5.8% |
| InventisBio 688382.SS | China | $1.19B | -41% | -61% | -563% | n/a | 10.4% | -60.6% |
| Seaport Therapeutics SPTX | United States | $1.15B | +34% | n/a | n/a | n/a | n/a | n/a |
| Jiuzhitang 000989.SZ | China | $1.19B | -13% | +46% | 19% | 22.7× | -3.7% | -9.0% |
| MedinCell MEDCL.PA | France | $1.15B | -1% | -23% | -131% | n/a | n/a | n/a |
| Changzhou Qianhong Bio-Pharma 002550.SZ | China | $1.21B | -8% | -2% | 15% | 19.6× | 4.5% | -1.2% |
| Shanghai Yizhong Pharmaceutical 688091.SS | China | $1.13B | -34% | +32% | 14% | n/a | n/a | n/a |
| Aurisco Pharmaceutical 605116.SS | China | $1.13B | -18% | +9% | 28% | 15.4× | 1.5% | +18.7% |
| Amphastar Pharmaceuticals AMPH | United States | $1.21B | +50% | +1% | 16% | 8.9× | 3.3% | +15.5% |
| Zhejiang Jolly Pharmaceutical 300181.SZ | China | $1.13B | -18% | +17% | 20% | 12.8× | 1.1% | +22.8% |
| Everest Medicines 1952.HK | Hong Kong | $1.22B | -20% | +193% | -5% | 26.9× | n/a | n/a |
| Omeros OMER | United States | $1.22B | +14% | n/a | -190% | 7.7× | n/a | n/a |
| ST Pharm 237690.KS | South Korea | $1.12B | -52% | +26% | 18% | 27.9× | n/a | n/a |
| Shandong Lukang Pharmaceutical 600789.SS | China | $1.11B | -13% | -7% | 3% | n/a | 3.3% | +6.5% |
| Blue Jet Healthcare BLUEJET.NS | India | $1.11B | +13% | -28% | 28% | 32.5× | 49.0% | +13.8% |
| Bio-Thera Solutions 688177.SS | China | $1.10B | -14% | +24% | -44% | n/a | n/a | n/a |